Evaluation of Miricorilant on Liver Fat in Patients With MASLD — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Evaluation of Miricorilant on Liver Fat in Patients With MASLD — Stella

Recruiting

Back to Nonalcoholic Steatohepatitis (NASH) trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

United States

University of Missouri, Columbia, Missouri

Key details

Phase

Early testing

Sponsor

Corcept Therapeutics

Collaborators

University of Missouri-Columbia

Enrollment target

~8 participants

Started

August 2025

Primary completion

May 2026

Age range

18 Years – 75 Years

Last updated February 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov